Apyx Medical Q1 revenue $12.5M (+32% YoY); raises FY2026 guidance

Apyx Medical Corp

Total revenue $12.5M, up 32% YoY; Surgical Aesthetics grew 36% to $10.7M.
Net loss narrowed to $2.1M ($0.05 loss per share) from $4.2M ($0.10 loss).
Adjusted EBITDA loss improved to $0.3M from $2.4M in prior year.
Raised FY2026 revenue guidance to $59M-$60M from prior $57.5M-$58.5M.
International sales strong, especially South Korea; Renuvion won NewBeauty award.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Apyx Medical Corp reported the first quarter ended March 31, 2026 results: revenue total revenue of $12.5 million, net income Net loss attributable to stockholders of $2.1 million, EPS $0.05 per share. Guidance raised.

Period: the first quarter ended March 31, 2026
Revenue: total revenue of $12.5 million
Net income: Net loss attributable to stockholders of $2.1 million
EPS: $0.05 per share
Guidance: raised
Result: reported results

Exact text from the filing

99.1) --- EX-99.1 2 ex_905122.htm EXHIBIT 99.1 ex_905122.htm EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2026 Financial Results • Reported total revenue of $12.5 million in the first quarter of 2026 primarily driven by 36% growth in the Surgical Aesthetics segment • Raised total revenue guidance for FY2026 to a range of $59.0 million to $60.0

View on SEC.gov

Browse all earnings releases →

Apyx Medical Corp filing history →

Source: SEC EDGAR

accession 0001437749-26-015352

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.